Sign in Subscribe
Securities law

Investigation into Alto Neuroscience Securities Class Action

Strategic Insights

— 1 min read

Alto Neuroscience, Inc. ("Alto" or the "Company"), a leading developer of novel therapies for central nervous system ("CNS") disorders, including major depressive disorder (MDD), has been at the center of a federal securities class action filed against the Company. The suit alleges that Alto and its executives violated federal securities laws by making false and/or misleading statements regarding the effectiveness of ALTO-100, the Company's treatment for MDD. The investigation, led by Faruqi & Faruqi, LLP, a leading national securities law firm, aims to seek the role of lead plaintiff in the class action and recover losses for investors who suffered significant financial losses due to Alto's alleged misconduct.

Key Takeaways:

  • The federal securities class action alleges that Alto and its executives made false and/or misleading statements regarding the effectiveness of ALTO-100, a treatment for MDD, which led to the Company's stock price falling $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.
  • The suit claims that Alto's business and/or financial prospects were overstated, leading to the Company's public statements being materially false and misleading.
  • Investors who purchased or otherwise acquired stock of Alto common stock during the period from February 2, 2024, to October 22, 2024, may be eligible to participate in the class action.
  • Faruqi & Faruqi, LLP is investigating potential claims against Alto and reminds investors of the September 19, 2025, deadline to seek the role of lead plaintiff in the class action.
  • The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members.

Statistics:

  • The Alto Neuroscience class action filing resulted in a $10.17 per share, or 69.99%, drop in the stock price to close at $4.36 per share on October 23, 2024.
  • The Company's stock price fell significantly on the news of ALTO-100's primary endpoint failure, indicating the impact of the alleged misconduct on investor sentiment.
  • The investigation aims to recover losses for investors who suffered financial losses due to Alto's alleged misconduct.

Sources:

  • "Faruqi & Faruqi, LLP Securities Litigation Partner Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options" (July 29, 2025 /PRNewswire/)
  • .

Read more